DNL/moscatillin might safely provide an alternative way to prevent and/or manage patients with the persistent hypoxia/ischemia associated progression that occurs in various developmental vascular disorders such as Norrie disease; this might occur via a downregulation of the level of PLGF and an upregulation of the concentration of NDP. This evidence concerns the gene PGF and Norrie disease.